These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17704399)

  • 21. Editorial comment on: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
    Terris MK
    Eur Urol; 2009 Feb; 55(2):392; discussion 393. PubMed ID: 18353530
    [No Abstract]   [Full Text] [Related]  

  • 22. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer.
    Walz J; Gallina A; Saad F; Montorsi F; Perrotte P; Shariat SF; Jeldres C; Graefen M; Bénard F; McCormack M; Valiquette L; Karakiewicz PI
    J Clin Oncol; 2007 Aug; 25(24):3576-81. PubMed ID: 17704404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing individual risk for prostate cancer.
    Nam RK; Toi A; Klotz LH; Trachtenberg J; Jewett MA; Appu S; Loblaw DA; Sugar L; Narod SA; Kattan MW
    J Clin Oncol; 2007 Aug; 25(24):3582-8. PubMed ID: 17704405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in prostate cancer treatment.
    Saca-Hazboun H
    ONS Connect; 2008 Sep; 23(9):8-12. PubMed ID: 18807706
    [No Abstract]   [Full Text] [Related]  

  • 25. Key developments in men's health.
    Kirby M
    Practitioner; 2000 Sep; 244(1614):728, 733-6. PubMed ID: 11048369
    [No Abstract]   [Full Text] [Related]  

  • 26. [Prostate carcinoma in the elderly].
    Ravaud A; Pasticier G; Davin JL; Demeaux H; Maire JP
    Bull Cancer; 2008 May; 95 FMC Onco():F65-9. PubMed ID: 18511369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Practice guideline 'Prostate cancer: diagnosis and treatment'].
    de Reijke TM; Battermann JJ; van Moorselaar RJ; de Jong IJ; Visser AP; Burgers JS
    Ned Tijdschr Geneeskd; 2008 Aug; 152(32):1771-5. PubMed ID: 18754308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Editorial comment on: development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy.
    Kattan MW
    Eur Urol; 2008 Sep; 54(3):611. PubMed ID: 18207318
    [No Abstract]   [Full Text] [Related]  

  • 29. More about prostate cancer--expectant management versus treatment.
    Anscher MS
    N C Med J; 1999; 60(6):313-4. PubMed ID: 10581934
    [No Abstract]   [Full Text] [Related]  

  • 30. Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels.
    Ide H; Yasuda M; Nishio K; Saito K; Isotani S; Kamiyama Y; Muto S; Horie S
    Anticancer Res; 2008; 28(4C):2487-92. PubMed ID: 18751439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance.
    Nakanishi H; Wang X; Ochiai A; Trpkov K; Yilmaz A; Donnelly JB; Davis JW; Troncoso P; Babaian RJ
    Cancer; 2007 Dec; 110(11):2441-7. PubMed ID: 17932909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate cancer nomograms are superior to neural networks.
    Karakiewicz PI; Chun FK; Briganti A; Perrotte P; McCormack M; Bénard F; Valiquette L; Graefen M; Saad F
    Can J Urol; 2006 Apr; 13 Suppl 2():18-25. PubMed ID: 16672124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.
    Schröder FH; Roobol MJ
    Curr Opin Urol; 2009 May; 19(3):227-31. PubMed ID: 19357513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.
    Kawamura K; Suzuki H; Kamiya N; Imamoto T; Yano M; Miura J; Shimbo M; Suzuki N; Nakatsu H; Ichikawa T
    Int J Urol; 2008 Jul; 15(7):598-603. PubMed ID: 18462353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Period analysis of prostate cancer survival.
    Wilding G; Remington P
    J Clin Oncol; 2005 Jan; 23(3):407-9. PubMed ID: 15572729
    [No Abstract]   [Full Text] [Related]  

  • 36. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice.
    Dong F; Kattan MW; Steyerberg EW; Jones JS; Stephenson AJ; Schröder FH; Klein EA
    J Urol; 2008 Jul; 180(1):150-4; discussion 154. PubMed ID: 18485398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomolecular markers of outcome prediction in prostate cancer.
    Lopergolo A; Zaffaroni N
    Cancer; 2009 Jul; 115(13 Suppl):3058-67. PubMed ID: 19544547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An updated catalog of prostate cancer predictive tools.
    Shariat SF; Karakiewicz PI; Roehrborn CG; Kattan MW
    Cancer; 2008 Dec; 113(11):3075-99. PubMed ID: 18823041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Watchful waiting in prostate cancer.
    Health News; 2004 Aug; 10(8):13. PubMed ID: 15551464
    [No Abstract]   [Full Text] [Related]  

  • 40. The current state of brachytherapy nomograms for patients with clinically localized prostate cancer.
    Nguyen CT; Zelefsky MJ; Kattan MW
    Cancer; 2009 Jul; 115(13 Suppl):3121-7. PubMed ID: 19544540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.